Compare Davita Inc (DVA) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares TIPS Bond ETF — how do they compare? Davita Inc trades at $227.51 (market cap $14.92B), while iShares TIPS Bond ETF trades at $108.05. The key difference: Davita Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| DVA | TIP | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Fixed Income |
52-Week High | $235.71 | $112.20 |
52-Week Low | $103.87 | $107.91 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
TIP trades at $107.91, down 0.2% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing fixed-income assets. Dividend payments are scheduled for mid-2026, providing income visibility.
Outlook remains cautious due to technical weakness and macroeconomic pressures from potential Fed rate hikes. Risks include interest rate sensitivity and market sentiment shifts, while the dividend yield offers a defensive cushion. Investors should monitor earnings reports for fundamental clarity amid the bearish trend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
